Moonshot AI Raises $3.5B, Valuation Jumps to $35B

What happened

Moonshot AI, the Chinese startup behind the Kimi model family, has closed a $3.5 billion funding round that pushes its valuation to $35 billion, according to reporting on the deal 1. The raise is being framed as a direct challenge to OpenAI and Anthropic, with Moonshot's newest model, Kimi-K3, positioned as a rival to the leading American systems 1. Coverage of the round ties it to China's broader AI ambitions and notes that Moonshot is also weighing IPO plans, suggesting the company sees this raise as a step toward going public rather than a terminal private round 1.

The Moonshot news lands amid a wider wave of capital moving into AI infrastructure and Chinese AI competitors alike. Eliyan, a Silicon Valley startup working on the data-transfer bottlenecks between AI chips inside data centers, separately raised $145 million at a $1 billion valuation, according to Reuters reporting picked up by KELO 5. That deal is far smaller than Moonshot's, but it underscores how investor appetite extends beyond flashy model-makers into the plumbing that supports them.

Meanwhile, DeepSeek — Moonshot's better-known domestic rival and the company that rattled Western AI markets earlier with its low-cost model releases — has reportedly hit the brakes on its own fundraising. Seeking Alpha reports that DeepSeek paused a 10 billion yuan raise amid regulatory scrutiny and sensitivity around Nvidia chip access, even as the company eyes an eventual IPO 4. A second account, from thetechedvocate.org citing GuruFocus, goes further, tying the pause specifically to controversial remarks made by DeepSeek founder Liang Wenfeng about the U.S.-China AI rivalry, and dating the freeze to July 26, 2026, with DeepSeek's valuation at the time pegged around $5 billion 3.

A separate thread in the coverage, unrelated to any single funding round, comes from Fortune's report on a medical AI study that found the same failure pattern — dangerous omissions in clinical answers — across OpenEvidence, OpenAI, Anthropic, and Doximity systems 2. It doesn't bear on Moonshot or DeepSeek's fundraising directly, but it lands as a reminder that capital and valuation gains are outpacing proof that these systems are safe for high-stakes use 2.

Where the reporting agrees

All the funding-specific sources agree that Chinese AI firms are commanding enormous valuations relative to their age and that Nvidia chip access and IPO strategy are recurring pressure points. Both DeepSeek accounts agree the company paused a round rather than closed one, and both connect the pause to some form of external controversy — regulatory or reputational — rather than a simple lack of investor interest 34. Both also note DeepSeek is still eyeing a public listing despite the freeze 34. The Moonshot and Eliyan stories, though covering different scales of company, agree on the general climate: money is still flowing rapidly into AI, whether toward frontier model developers chasing OpenAI and Anthropic or toward infrastructure players solving chip-to-chip bottlenecks 15.

Where it doesn't

The two DeepSeek accounts diverge on specifics that matter. Seeking Alpha attributes the pause to "scrutiny and Nvidia chip sensitivity" without naming a precise trigger 4. Thetechedvocate.org's account, however, is far more specific and dramatic, attributing the freeze directly to controversial statements Liang Wenfeng made about the U.S.-China AI competition, and it assigns a hard date — July 26, 2026 — and a valuation figure of roughly $5 billion 3. That valuation is a fraction of Moonshot's reported $35 billion, and the date itself is notable: it places the DeepSeek episode in the near future relative to when this reporting appears, which should be read with caution given the source's lower profile and the extraordinary specificity of a founder-comments-triggered halt. No other outlet in this set corroborates the Liang Wenfeng comments angle or the July 26 date. The Moonshot valuation and round size, by contrast, come from a single sourced figure as well, with no second outlet independently confirming the $3.5 billion or $35 billion numbers.

The best-supported reading

Treat the Moonshot figures as reported but unconfirmed by a second outlet, and treat the DeepSeek founder-comments explanation as the less reliable of two competing accounts of the same pause. The more conservative Seeking Alpha framing — scrutiny plus chip sensitivity — fits a pattern already well established in Chinese AI coverage, where Nvidia export controls and regulatory attention routinely complicate fundraising, and it doesn't require accepting an unverified, oddly specific date and quote attribution from a lower-profile aggregator. What both DeepSeek pieces agree on, and what matters most, is that even China's most prominent AI challenger has hit friction that Moonshot, at least for now, has not. Layered against Eliyan's raise and the Fortune study on clinical AI's shared blind spots, the picture is one of a market still pouring in capital while the underlying products and geopolitics remain unsettled.